# Erleada (apalutamide) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/apalutamide

> The FDA approved Erleada (apalutamide), sponsored by JOHNSON & JOHNSON (JNJ), on February 14, 2018.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Erleada (apalutamide) |
| Codes | JNJ-56021927 |
| Sponsor | JOHNSON & JOHNSON (JNJ) https://sec-api.dev/companies/jnj/catalysts |
| Indications | [Metastatic Castrate-sensitive Prostate Cancer](https://sec-api.dev/indications/metastatic-castrate-sensitive-prostate-cancer), [Prostatic Neoplasms](https://sec-api.dev/indications/prostatic-neoplasms) |
| Modality |  |
| FDA designations | priority review |

## Timeline

### February 14, 2018: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA210951 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20180214, review_priority PRIORITY; sponsor_name JANSSEN BIOTECH; product ERLEADA (APALUTAMIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210951%22

### November 20, 2020: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA210951 SUPPL-4 (Efficacy): submission_status AP, submission_status_date 20201120, review_priority PRIORITY; sponsor_name JANSSEN BIOTECH; product ERLEADA (APALUTAMIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210951%22

### September 7, 2021: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA210951 SUPPL-6 (Efficacy): submission_status AP, submission_status_date 20210907, review_priority STANDARD; sponsor_name JANSSEN BIOTECH; product ERLEADA (APALUTAMIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210951%22

### December 19, 2023: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA210951 SUPPL-14 (Efficacy): submission_status AP, submission_status_date 20231219, review_priority STANDARD; sponsor_name JANSSEN BIOTECH; product ERLEADA (APALUTAMIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210951%22

### Oct 2026 to Jan 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Metastatic Castrate-sensitive Prostate Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05884398 (A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-12 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." https://clinicaltrials.gov/study/NCT05884398

### October 2026: primary completion

- Status: delayed. Date confidence: month. Stage: 3. Indication: Metastatic Castrate-sensitive Prostate Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05884398 (A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-12 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." https://clinicaltrials.gov/study/NCT05884398

### December 2026: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Prostatic Neoplasms.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03767244 (A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-01 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." https://clinicaltrials.gov/study/NCT03767244

### Dec 2026 to Mar 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Prostatic Neoplasms.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03767244 (A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-01 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." https://clinicaltrials.gov/study/NCT03767244

### Aug to Nov 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Prostatic Neoplasms.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04557059 (A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-08-27 (ESTIMATED); Lead Sponsor Janssen Pharmaceutica N.V., Belgium." https://clinicaltrials.gov/study/NCT04557059

### August 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Prostatic Neoplasms.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04557059 (A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-08-27 (ESTIMATED); Lead Sponsor Janssen Pharmaceutica N.V., Belgium." https://clinicaltrials.gov/study/NCT04557059

## Same indication

- [JNJ-101556143](https://sec-api.dev/pdufa/jnj-101556143) (JNJ)

Calendar months: [October 2026](https://sec-api.dev/fda-calendar/2026-10), [December 2026](https://sec-api.dev/fda-calendar/2026-12)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/apalutamide.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Erleada (apalutamide) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/apalutamide

```bibtex
@misc{secapidev_pdufa_apalutamide_20261116,
  title        = {Erleada (apalutamide) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/apalutamide}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_apalutamide_20261116","title":"Erleada (apalutamide) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/apalutamide","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
